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Abstract 
Multidrug transporters are membrane proteins that are able to expel a broad range of toxic molecules from the cell. In 
humans, the overexpression f the multidrug resistance P-glycoprotein (Pgp) and the multidrug resistance-associated protein 
MRP1 (MRP) is a principal cause of resistance of cancers to chemotherapy. These multidrug transporters belong to the 
ATP-binding cassette (ABC) family of transport proteins that utilize the energy of ATP hydrolysis for activity. In 
microorganisms, multidrug transporters play an important role in conferring antibiotic resistance on pathogens. In the last 
decade, homologs of human Pgp and MRP have been found in microorganisms such as Plasmodium falciparum, Candida 
albicans, Saccharomyces cerevisiae and, more recently, in Lactococcus lactis. In this review, we will summarize the current 
state of knowledge on three major aspects of microbial ABC-type multidrug transporters: (i) the functional and structural 
similarities among these proteins in prokaryotic and eukaryotic cells, (ii) the molecular mechanism ofthese transporters, and 
(iii) their potential physiological role. © 1998 Elsevier Science B.V. 
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1. Introduction 
Organisms ranging from bacteria to man have 
developed versatile mechanisms to resist cytotoxic 
drugs. Examples are the enzymatic degradation or 
inactivation of drugs [1], and the alteration of drug 
targets [2]. In addition, all cells possess membrane 
proteins which catalyse transmembrane drug trans- 
port, and hence are able to overcome cell cytotoxicity 
by lowering the cytoplasmic drug concentration [3- 
5]. Some drug transporters are fairly specific for a 
given drug or class of drugs, but the so-called 
multidrug transporters have specificity for compounds 
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with very different chemical structures and cellular 
targets. 
Multidrug transport proteins fall into a limited 
number of families [5]. One of the largest of these 
families belongs to the ATP-binding cassette (ABC) 
superfamily [6]. Well-known members are the human 
MDR1 gene-encoded multidrug resistance P- 
glycoprotein (Pgp) [7] and the human multidrug 
resistance-associated protein MRP1 (MRP) [8] plas- 
ma membrane transporters, which catalyse the ATP- 
dependent extrusion of anti-tumor drugs during the 
chemotherapy of cancer cells. 
The number of ABC-type multidrug transporters 
identified in microorganisms i vast and rapidly 
expanding. Based on (i) the alignment analysis of 
amino acid residues that comprise the nucleotide- 
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binding domain(s), (ii) protein topology, and (iii) 
drug specificity, the ABC family of drug transporters 
can be divided into two major clusters: the Pgp 
cluster and the MRP cluster. In this review, we will 
give a comprehensive overview of these clusters 
using selected examples in pro- and eukaryotic cells. 
In addition, the review will focus on the remarkable 
conservation of function among ABC-type drug 
transporters, which suggests a common molecular 
mechanism of these proteins in all living cells. 
2. ABC transporters 
2.1. Pgp cluster 
Members of the Pgp cluster play an important role 
in microbial resistance to neutral or positively 
charged, amphiphilic drugs (Table 1). These trans- 
porters function in human pathogens such as Plas- 
modium falciparum (pfMDR1) [9], Entamoeba his- 
tolytica (ehPgp) [lo], or Leishmania donovani 
(ldMDR1) [ll]. In addition, infections in immuno- 
deficiency patients are often caused by the pathogenic 
yeast Candida albicans which expresses Cdrlp, an 
ABC transporter which confers antifungal resistance 
[ 121. ABC proteins in the non-pathogenic Sac- 
charomyces cerevisiae include the multidrug trans- 
porters PdrSp [ 131 and Snq2p [ 141. Pgp cluster 
members have also been identified in bacteria. In 
Streptomyces strains, dedicated transporters such as 
DrrAB [ 151 mediate the excretion of specific anti- 
biotics to ensure self-resistance to the antibiotics that 
Table 1 
Examples of ABC-type multidrug transporters in microorganisms 
Protein Organism Accession NoP 
Pgp cluster pfMDR1 Plasmodium falciparum GB A32547 
ehPgp Entamoeba histolytica GB M88599 
1dMDRl Leishmania donovani GB LO1572 
Cdrlp Candida albicnns GB X77589 
PdrSp Saccharomyces crrevisiue GB L19922 
Snq2p Saccharomyces cerevisine GB 248008 
LmrA Lactococcus lactis GB U63741 
MRP cluster Ycflp Saccharomyces cerevisiae GB 248179 
Yorlp Saccharomyces cerevisiur GB 273066 
1tPgpA Leishmania tarentolae GB A34207 
ceMRP1 Caenorhabditis elegans EM 466260 
“ATP-binding cassette superfamily 161. 
hAccession number: GB, Genbank; EM, EMBL. 
they produce. A true prokaryotic ABC-type multidrug 
transporter with significant sequence identity to Pgp 
in both the ABC and membrane domains has been 
found in Lactococcus lactis (LmrA) [ 161. The se- 
quence conservation between LmrA and Pgp includes 
particular regions (e.g., the first cytoplasmic loop and 
the region comprising transmembrane segments V and 
VI) that have been implicated as determinants of drug 
recognition and binding by Pgp. Interestingly, LmrA 
shares significant sequence identity with the hop- 
resistance protein HorA in Luctobacillus brevis [ 171, 
and with the products of putative open reading frames 
in Bacillus subtilis, Staphylococcus aureus, Es- 
cherichia coli, Helicobacter pylori, Haemophilus 
inJluenzae, and Mycoplasma genitalium (Table 2). 
Thus, homologs of LmrA may play an important role 
in the multidrug resistance phenotype of pathogenic 
bacteria. 
Like Pgp, a number of ABC transporters in micro- 
organisms are expressed as single multifunctional 
polypeptides containing two homologous halves, each 
with an ABC domain and a membrane domain. The 
membrane domains are usually composed of six 
putative o-helical transmembrane segments (Fig. 1). 
Certain ABC proteins, such as lactococcal LmrA and 
E. coli cr-hemolysin transporter HlyB [ 181, have half 
the size of Pgp with only a single transmembrane 
domain and ABC domain. The notion that two of 
these half-molecules must cooperate to the formation 
of a single transporter is, amongst others, supported 
by the observation that the independent expression of 
each half of the a-mating pheromone transporter 
Ste6p in yeast cells does not yield a functional 
transporter, while simultaneous expression of both 
halves does [ 191. In drug transporters such as DrrAB, 
the two membrane domains are fused into a single 
polypeptide which is associated with a second poly- 
peptide containing the two ABC domains. 
2.2. MRP cluster 
Members of the MRP cluster contain an N-terminal 
membrane-bound domain consisting of five putative 
a-helical transmembrane segments, which is followed 
by two homologous halves each with six putative 
o-helical transmembrane segments and an ABC 
domain (Fig. 1) [20-221. Like MRPl, MRP 
homologs in microorganisms mediate the extrusion of 
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Table 2 
Homologs of ImrA” in bacteria 
Organism 
Lactobacillus brevis 
Bacillus subtilis 
Staphylococcus aureus 
Escherichia coli 
Helicobacter pylon’ 
Haemophilus influenzae 
Mvcovlasma Penitalium 
Gene Predicted length (aa) Identity (%) 
horAb 583 53 
yvcc 589 43 
y WA 575 35 
.yknV 604 31 
YW 604 30 
abcA 575 33 
msbA 582 30 
mdlA 590 28 
mdlB 593 29 
cYdC 573 27 
CYdD 588 25 
HP1082 552 27 
HI0060 587 28 
HI1051 614 26 
MGO15 589 25 
Ref. 
[I71 
1531 
154.551 
[561 
[571 
I.581 
“LmrA is a 590.aa polypeptide with six transmembrane segments in the N-terminal hydrophobic domain, followed by the ABC domain [16,35]. 
bHorA functions as a multidrug transporter 1171. 
‘Unpublished data, Genbank accession no. U29478. 
A 
a b d 
Fig. 1. Predicted topology of ABC-type multidrug transporters in microorganisms. (A) Pgp cluster. The typical ABC transporter of this cluster contains four 
membrane-associated omains. Two of these domains are highly hydrophobic and each consist of six putative transmembrane segments in a-helical 
configuration. These transmembrane domains (TMD) form the pathway through which substrate crosses the membrane, and are believed to determine, in 
part, the substrate specificity of the transporter. The other two domains are nucleotide-binding domains (NBD) which are peripherally located at the 
cytoplasmic face of the membrane, and which contain the Walker A and B motifs and the ABC signature [6]. The individual domains are frequently fused 
into a single multifunctional polypeptide with a {TMD-NBD}, configuration (a) or {NBD-TMD}2 configuration (b) or expressed on two separate 
polypeptides with {TMD),{NBD), configurations (c). ‘Half-size’ transporters with a {TMD-NBD} topology (d) or {NBD-TMD} topology (e) are also 
frequently found. Examples of the various ABC transporters are (a) Plasmodium falciparum pfMDR1 [9], (b) Saccharomyces cerevisiae PdrSp [ 131 and 
Snq2p [14], (c) Streptomyces peuceticus DrrAB [15], (d) Lactococcus lactis LmrA [16], and (e) S. cerevisiae ADPlp [59]. (B) MRP cluster. The 
N-terminal transmembrane domain consists of five putative a-helical transmembrane segments, and is followed by two homologous halves each with six 
putative u-helical transmembrane segments and a NBD. Representative members of this cluster are mentioned in the text. 
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a wide variety of organic anions, such as carbox- 
yfluorescein derivatives, bis(glutathionate)cadmium, 
and other glutathione S-conjugates. The best char- 
acterized members of this cluster include: (i) the 
yeast cadmium factor (Ycflp) [23,24] and Yorl 
protein [25] in S. cerevisiae, (ii) transporters associ- 
ated with heavy metal resistance in Leishmania 
species (lmPgpA) [26,27] and the nematode Caenor- 
habditis elegans (ceMRP1) [28], and (iii) the bile 
acid transporter Batlp in S. cerevisiae [29] (Table 1). 
The BCECF (2',7'-bis-(2-carboxyethyl)-5(and 6)-car- 
boxyfluorescein) transporter in L. lactis [30] may be 
the first prokaryotic example of this cluster. 
3. Functional similarity 
The structural similarity between ABC-type drug 
transporters can result in functional similarity. Albeit 
at low efficiency, the mouse Pgp-homolog mdr3 [31] 
and Plasmodium pfMdrl [32] can complement yeast 
Ste6p, thus restoring mating in a Aste6 sterile yeast 
strain. MRP1 can fully complement the Ycfl protein 
in a Aycfl cadmium-sensitive strain of S. cerevisiae 
[33], and partially complement S e6p in the sterile 
Aste6 null mutant of this organism [34]. 
The functional substitution of one ABC-type drug 
transporter by another is not only confined to eukary- 
otic transport proteins. The bacterial LmrA protein 
was able to functionally complement human Pgp in 
human lung fibroblast cells [35]. Surprisingly, LmrA 
was even targeted to the plasma membrane. The 
pharmacological characteristics of LmrA and Pgp- 
expressing lung fibroblasts were very similar, and the 
affinities of both proteins for vinblastine and mag- 
nesium-ATP indistinguishable. Blockers of P-glycop- 
rotein-mediated multidrug resistance also inhibited 
LmrA-dependent drug resistance. Kinetic analysis of 
drug dissociation from LmrA expressed in plasma 
membranes of insect cells, revealed the presence of 
two allosterically linked drug binding sites indis- 
tinguishable from those of P-glycoprotein [36,37]. 
4. Transport mechanism 
The remarkable conservation of functional prop- 
erties between ABC-type drug transporters suggests a 
common molecular mechanism of transport by these 
proteins in pro- and eukaryotic ells. Several models 
have been postulated for the pump function of 
multidrug transporters to explain their broad spe- 
cificity for chemically unrelated compounds. Drug 
translocation may involve substrate transport from the 
cytoplasm to the exterior via an aqueous pore with a 
flexible 'enzyme-like' substrate recognition site (con- 
ventional transport hypothesis) [38]. Alternatively, 
multidrug transporters could recognize the lipophilic 
drugs by their physical property to intercalate into the 
lipid bilayer, and transport drugs from the lipid 
bilayer to the exterior (vacuum cleaner hypothesis) 
[39], or from the inner leaflet o the outer leaflet of 
the lipid bilayer (flippase hypothesis) [40]. 
Recent evidence suggests that bacterial LmrA [41] 
and human Pgp [42,43] recognize drugs by their 
hydrophobic properties, and that both proteins trans- 
port these compounds from the cytoplasmic leaflet of 
the plasma membrane. This transport mechanism is
likely to be a more general mechanism for ABC 
transporters with hydrophobic substrates. The human 
MDR2 gene-encoded P-glycoprotein transports phos- 
phatidylcholine from the cytoplasmic leaflet of the 
bile canicular membrane of hepatocytes into the bile 
[44,45]. In addition, the E. coli a-hemolysin transpor- 
ter HlyB most likely binds the transport signal 
sequence of o~-hemolysin, when the signal sequence 
forms an amphiphilic helix that binds to the cyto- 
plasmic leaflet of the plasma membrane [46,47]. 
5. Concluding remarks 
Multidrug transporters are present in all living 
cells. Appreciation of the mechanism and physiologi- 
cal function of these transport proteins is crucial for 
the development of effective new drugs able to 
suppress multidrug resistance in clinical settings. It 
has been proposed that Pgp participates in the 
protection of human cells against hydrophobic xeno- 
biotics by active excretion of these compounds from 
the membrane into bile, urine, or the intestinal lumen, 
and by preventing their accumulation in critical 
organs such as the brain [48]. Likewise, a defense 
function can be envisioned for multidrug transporters 
in microorganisms. These organisms encounter 
numerous hydrophobic ompounds in their habitat 
H.W. van Veen, W3V. Konings / Biochimica et Biophysica Acta 1365 (1998) 31-36 35 
which will accumulate in phospholipid bilayers (for a 
review on the membrane toxicity of various lipophilic 
compounds, ee Sikkema et al. [49]). It is noteworthy 
that the natural environment of enteric microorga- 
nisms is enriched in toxic bile salts and fatty acids, 
and that these compounds are substrates for various 
multidrug transporters [50]. Alternatively, multidrug 
transporters may play a specific role in the transport 
of a common endogenous substrate, such as lipid 
[44,45,51,52], which remains to be established. 
Studies on multidrug transporters in microorganisms 
could bring valuable information about the general 
molecular properties of these transport systems in 
prokaryotic and eukaryotic ells, and their implica- 
tions in human disease. 
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